Clinical Trials Logo
  1. Home
  2. Other
  3. NCT04727632

[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE Trial

Estrogen Receptor Positive Breast Cancer Clinical Trial

Official title:
[18F]Fluoroestradiol-PET/CT Companion Imaging Study to the FORESEE: Functional Precision Oncology for Metastatic Breast Cancer Feasibility Trial

Clinical Trial Summary

This protocol is a companion imaging study that will add FES-PET/CT imaging to the FORESEE trial at HCI. This study will establish the feasibility of using FES-PET/CT imaging to guide therapeutic decision making for functional precision oncology trials. The unique ability of FES-PET/CT to show absence of functional estrogen receptors throughout the entire body may improve confidence among research oncologists that an ER+ metastatic breast cancer patient is truly refractory to hormonal therapies which is a critical determination in the study design of the FORESEE trial.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT04727632
Study type Interventional
Source University of Utah
Contact Paige Nielsen
Phone 801-585-5942
Email paige.nielsen@hci.utah.edu
Status Recruiting
Phase Early Phase 1
Start date March 31, 2021
Completion date April 30, 2026
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT01984138 - REVIVE: Replens Versus Intra-Vaginal Estrogen for the Treatment of Vaginal Dryness on Aromatase Inhibitor Therapy Phase 2
Active, not recruiting NCT01996046 - FDG PET/CT in Breast Cancer Bone Mets
Completed NCT01219699 - A Study of BYL719 in Adult Patients With Advanced Solid Malignancies, Whose Tumors Have an Alteration of the PIK3CA Gene Phase 1
Active, not recruiting NCT02409316 - [18F]FES PET/CT in Endocrine Refractory Breast Cancer Phase 2
Active, not recruiting NCT01992952 - Fulvestrant +/- Akt Inhibition in Advanced Aromatase Inhibitor Resistant Breast Cancer Phase 1/Phase 2
Terminated NCT02000375 - A Phase II Study Evaluating the Role of Androgen Receptors as Targets for Therapy of Pre-treated Post-menopausal Patients With ER/PgR-negative/AR-positive or ER and/or PgRpositive/ AR-positive Metastatic Breast Cancer (ARTT) Phase 2
Active, not recruiting NCT02668666 - Palbociclib in Combination With Tamoxifen as First Line Therapy for Metastatic Hormone Receptor Positive Breast Cancer Phase 2
Completed NCT02820961 - Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer Phase 1
Active, not recruiting NCT02947685 - Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer Phase 3
Terminated NCT02823262 - A Breast Cancer Treatment Decision Aid for Women Aged 70 and Older N/A
Terminated NCT02414776 - Hydroxychloroquine in Metastatic Estrogen Receptor-Positive Breast Cancer Progressing on Hormonal Therapy Phase 1
Active, not recruiting NCT02216786 - A Randomized Study of AZD2014 in Combination With Fulvestrant in Metastatic or Advanced Breast Cancer Phase 2
Active, not recruiting NCT01765049 - Breast Density Change Predicting Response to Adjuvant Aromatase Inhibitor
Active, not recruiting NCT00066690 - Suppression of Ovarian Function With Either Tamoxifen or Exemestane Compared With Tamoxifen Alone in Treating Premenopausal Women With Hormone-Responsive Breast Cancer Phase 3
Active, not recruiting NCT02238808 - A Study to See Whether Estrogen Can Slow the Growth of Some ER Positive Breast Cancers Phase 2
Completed NCT02988986 - TAK-228 Plus Tamoxifen in Patients With ER-Positive, HER2-negative Breast Cancer Phase 2